



Narhex Life Sciences Ltd

Level 24, 44 St George's Terrace
PERTH WA 6000
P: +61-8-6211 5099
F: +61-8-9218 8875

ABN: 51 094 468 318

19 May 2015

Company Announcements Office
Australian Securities Exchange
10th Floor
20 Bond Street
SYDNEY NSW 2000

RESAPP TO PRESENT AT ASIA BIOTECH INVEST 2015

Current Clinical Study Update

The Directors of Narhex Life Sciences Limited ("**Narhex**" or the "**Company**" ASX: **NLS**) are pleased to announce that ResApp Diagnostics Pty Ltd ("**ResApp**") incoming Managing Director / CEO, Dr Tony Keating is presenting at the Asia Biotech Invest Conference in Hong Kong on 20 May 2015. Asia Biotech Invest, organised in partnership with Ausbiotech is the leading biotech investment conference in Asia, gathering over 150 of the world's leading biotech investors seeking new investment opportunities. Dr Keating will be making a ResApp company presentation following his participation in a panel discussion entitled, "Investing in the rapidly growing global digital health / health tech industry".

ResApp recently commenced a clinical study at Joondalup Health Campus ("**JHC**"), the largest hospital in Perth's Northern suburbs. The trial will gather data from approximately 150 patients with a variety of respiratory conditions with the aim of further optimising the ResApp algorithms for pneumonia and asthma as well as broadening the validation to other common respiratory conditions such as bronchitis, bronchiolitis and upper respiratory tract conditions. Recruitment is running to schedule with 60 patients currently enrolled. Preliminary results from this study are expected to be announced in late June. ResApp is currently finalising ethics approval to commence an additional study at a second major Australian hospital that will greatly increase the speed in which patient data can be acquired.

Narhex has released a Notice of Meeting to be held in Perth on 27 May 2015 to acquire 100% of ResApp subject to satisfaction of conditions precedent including recompliance with Chapters 1 and 2 of the ASX Listing Rules. A prospectus has been issued to facilitate a capital raising of at least \$2,500,000 to provide funding for ResApp and working capital for the Company.

About ResApp

ResApp through the exclusive licence it has been granted by the University of Queensland ("**UQ**") is developing mobile medical applications for the diagnosis and management of respiratory disease. The technology is based on a machine learning algorithm that uses sound alone to diagnose and measure the severity of a respiratory condition. The algorithm has been tested for pneumonia and asthma

For personal use only



diagnosis in a clinical proof of concept study of 91 patients by UQ through funding from the Bill and Melinda Gates Foundation. Addressable markets for this technology include the following:

1. At-home diagnosis and management of respiratory disease through direct sales to app consumers;
2. Licensing to large telehealth providers for “in consultation” diagnosis and assessment over mobile or the web; and
3. Working with organisations such as the World Health Organisation (WHO) to deliver tools for low-cost diagnosis and management of respiratory illness in the developing world.

The technology has been licensed to ResApp via UQ’s main commercialisation company UniQuest Pty Ltd (“**UniQuest**”). UniQuest is among the global leaders in commercialisation of university technologies and annual sales of products using UQ technology and licensed by UniQuest is approximately \$3b.


ResApp’s vision is to empower consumers to self-diagnose and manage respiratory disease by providing effective, affordable and practical mHealth apps without the need for additional hardware. Patients will be more informed about their health and be able to work more closely with their doctor to achieve better health outcomes. Cough is the most common single reason for a doctor visit, and in the US, over 100m primary care physician visits result in diagnosis of a respiratory disease. 15% of the world’s population suffer from chronic respiratory or pulmonary diseases such as asthma and COPD (chronic obstructive pulmonary disease), which require day-to-day disease management. The company will initially target a range of respiratory diseases including pneumonia, bronchitis, COPD and asthma and plans to expand its technology portfolio to encompass the entire spectrum of respiratory disease.

According to a recent Rock Health report, US venture capital investment in mHealth for the first half of 2014 represented \$2.4b, exceeding the total invested in 2013. Accenture recently predicted funding for digital health startups will reach \$6.5b in 2017.

Adam Sierakowski
Chairman

For personal use only

For personal use only

Res  pp
H E A L T H



Disclaimer

This presentation has been prepared by ResApp Diagnostics Pty Ltd (“ResApp”). The information contained in this presentation is a professional opinion only and is given in good faith. Certain information in this document has been derived from third parties and though ResApp has no reason to believe that it is not accurate, reliable or complete, it has not been independently audited or verified by ResApp. Any forward-looking statements included in this document involve subjective judgment and analysis and are subject to uncertainties, risks and contingencies, many of which are outside the control of, and may be unknown to, ResApp. In particular, they speak only as of the date of this document, they assume the success of ResApp’s strategies, and they are subject to significant regulatory, business, competitive and economic uncertainties and risks.

Actual future events may vary materially from the forward-looking statements and the assumptions on which the forward-looking statements are based. Recipients of this document (Recipients) are cautioned to not place undue reliance on such forward-looking statements. ResApp makes no representation or warranty as to the accuracy, reliability or completeness of information in this document and does not take responsibility for updating any information or correcting any error or omission which may become apparent after this document has been issued.

To the extent permitted by law, ResApp and its officers, employees, related bodies corporate and agents (Agents) disclaim all liability, direct, indirect or consequential (and whether or not arising out of the negligence, default or lack of care of ResApp and/or any of its Agents) for any loss or damage suffered by a Recipient or other persons arising out of, or in connection with, any use or reliance on this presentation or information.

This presentation is not an offer, invitation, solicitation or recommendation with respect to the subscription for, purchase or sale of any security, and neither this presentation nor anything in it shall form the basis for any contract or commitment whatsoever.

All amounts in Australian dollars unless stated otherwise.

A unique opportunity in the next generation of mobile health

Our vision is to empower consumers to self-diagnose and manage respiratory disease by providing effective, affordable and practical mHealth apps



- Developing the world's first clinically-tested, regulatory-approved respiratory diagnostic for smart devices with no additional hardware required
- Asthma and COPD management products also in development

ResApp has proposed an experienced team with technology, healthcare and capital markets backgrounds

<p>Dr Roger Aston Non-Executive Chairman* PhD (Manchester)</p>	<p>20 years' experience in the healthcare industry. Held Executive, Non-Executive Director or Chairman positions on a number of Boards. Formerly CEO of Mayne Pharma Group Limited and currently Director and Executive Chairman of PharmAust Limited, Chairman of Immuron Limited and Chairman of Oncosil Medical.</p>
<p>Dr Tony Keating Managing Director and Chief Executive Officer* PhD (UQ), Exec. Certificate (MIT Sloan), GAICD</p>	<p>Previously Director, Commercial Engagement at UniQuest. Over 9 years' experience in commercialising technology. Held roles as interim Chief Executive Officer and Non-Executive Director for a number of privately-held, venture capital funded start-up companies. Previously held business development and engineering management roles at Exa Corporation, a US-based software company.</p>
<p>Brian Leedman VP, Corporate BEc (UWA), MBA (UWA)</p>	<p>Investor relations and capital raising professional with a background in marketing. 10 years as Vice President, Investor Relations for Nasdaq/ASX listed, pSivida Corp. Co-founded Oncosil Medical and Imugene Limited. Chair of AusBiotech WA.</p>
<p>Dr Udantha Abeyratne Scientific Advisor PhD (Drexel)</p>	<p>Associate Professor of Biomedical Engineering at UQ and inventor of ResApp's platform technology. Over 17 years' experience in sound-based diagnosis of disease and 25 years experience in medical instrumentation and signal processing. His work has received funding from the Bill and Melinda Gates Foundation, the Australian Research Council, the Princess Alexandra Hospital Foundation, The University of Queensland and UniQuest Pty Ltd.</p>
<p>Dr Paul Porter Clinical Advisor MBBS FRACP</p>	<p>Consultant Paediatrician with subspecialty qualifications in Paediatric Emergency Medicine and General Paediatrics. Appointments at Princess Margaret Hospital for Children and Joondalup Health Campus. Clinical Lecturer in Paediatrics at UWA and a member of the Clinical Senate of WA.</p>


* Proposed to join ResApp on completion of transaction with NLS

Diagnosis of respiratory disease is the most common outcome from a doctor's visit



Strong growth in delivery of healthcare over the internet and mobile

For personal use only



- ✓ Lower costs
- ✓ Improved quality of care
- ✓ No travelling or waiting rooms
- ✓ Shorter consultations



75M

telehealth consultations
predicted in US for 2014

\$50-60B

total addressable market
for telehealth (US\$)



>30%


of all telehealth
consultations for acute
respiratory disease

56%

growth predicted
in US telehealth

Revolutionary technology for respiratory disease diagnosis and management

- ResApp has exclusively licensed technology developed by A/Prof Udantha Abeyratne from The University of Queensland
- Uses signatures in cough and breathing sounds to diagnose and measure severity of respiratory disease
- Uses machine learning technology
- Peer-reviewed clinical proof of concept study funded by the Bill and Melinda Gates Foundation
- Prototype app for pneumonia built and tested



	Sensitivity	Specificity
Pneumonia	94%	100%
Asthma	100%	80%

Multiple revenue streams tied to real customer value



'In consultation' diagnosis over mobile and/or the web.
Immediate access to a large pool of patients.



Direct to consumer distribution using Apple AppStore and Google Play.
In-app purchase per diagnostic test.
Pipeline to management apps.



Licensing to reach huge installed base of devices.



Big Data Insights

Moving quickly to complete clinical studies at major Australian hospitals and overseas

- Clinical study commenced at Joondalup Health Campus in Perth
 - 60 subjects enrolled since 23 March 2015
 - Targeting 150 patients with a variety of respiratory conditions
 - Approximately 3 months for preliminary results
- Ethics application underway at second Perth hospital
- Discussions underway with a major humanitarian organisation to fund a trial in developing countries

Proposed transaction with Narhex Life Sciences

	Minimum Subscription	Full Subscription
Share price		\$0.009
12 month trading range		\$0.002 - \$0.010
Current cash balance (as of 1 April 2015)		\$881,000¹
Current Issued capital (pre-consolidation)		664,729,407 ²
Issued capital (post-consolidation)		249,273,527
Options issued in sophisticated placement		90,000,000 ³
Offer price per share	\$0.02 (equivalent to \$0.0075 pre-consolidation)	
Shares to be offered under Public Offer	125,000,000	200,000,000
Cash raised under the Public Offer	\$2,500,000	\$4,000,000
Vendor Offer		93,750,000 ⁴
Facilitation Offer		18,749,999
Total shares on issue following transaction	486,773,526 ⁵	561,773,526 ⁵
Market capital at issue price	\$9,735,471	\$11,235,471

1. Includes \$361k cash in NLS + \$310k receivables + \$210k loan advanced to ResApp; 2. Includes 10,000,000 shares to be issued to Trident Capital under second tranche of sophisticated placement; 3. Exercise price \$0.01, Expiry 31 December 2016; 4. An additional 93,750,000 vendor performance shares to be issued upon ResApp or the Company achieving \$20m in gross revenues, or an acquisition event by NLS.; 5. Excludes performance vendor shares

Summary

- Revolutionary technology – diagnosis and management of respiratory disease **without the need for additional hardware**
- Targeting a **huge market**, cough is the most common reason for visiting a GP
- **Successful clinical proof of concept** funded by the Bill and Melinda Gates Foundation
- **Clinical study commenced** at a major Australian hospital, further studies to commence in Q2 2015
- Leverage growth of telehealth to launch product within 18 months and reach millions of patients quickly
- Multiple large revenue streams tied to value



Dr Tony Keating

tony@resapphealth.com.au

Asia Biotech Invest 2015, Sheraton Hotel & Towers, Hong Kong
20 May 2015